Thus, it is highly significant to develop new tumor-specific targeted therapy to improve the clinical outcomes in GBM patients with less side effects due to non-specific targeting.
← all excerpts
MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44.
1
—
—